Federal Judge Slams Trump Administration's Transphobic Witch Hunt, Blocks Harassment of Medical Groups

In a decisive rebuke of the Trump administration’s escalating war on transgender people, Chief Judge James E. Boasberg of the U.S. District Court for the District of Columbia has blocked the Federal Trade Commission (FTC) from enforcing sweeping subpoenas against two major medical organizations supporting transgender health.

The cases, Endocrine Society v. FTC and World Professional Association for Transgender Health (WPATH) v. FTC, challenged the FTC’s Civil Investigative Demands (CIDs) issued in January 2026. These demands sought unprecedented access to decades of internal communications, financial records, advocacy materials, and member information—some dating back to 1979—effectively weaponizing government power to intimidate and silence.

Judge Boasberg’s rulings found that the FTC’s actions likely violated the First Amendment rights of these organizations by retaliating against their protected speech supporting gender-affirming care. The judge highlighted “extensive evidence of animus” behind the subpoenas, describing the government’s justifications as “wafer-thin” and lacking any genuine investigative basis.

This targeting is part of a broader Trump-era campaign to suppress transgender rights and medical care. It follows a series of attacks including the Kennedy Declaration, which forced over 40 hospital systems to shutter trans youth programs before being struck down by a federal court, CMS proposals to bar Medicare and Medicaid hospitals from providing gender-affirming care, and Department of Justice subpoenas to hospitals nationwide—many of which judges have dismissed as retaliatory smokescreens.

The evidence of animus cited by Judge Boasberg is stark. It includes Trump’s executive orders branding gender identity as “subversive” and gender-affirming care as “mutilation”; FTC Chair Andrew Ferguson’s pre-appointment pledge to “fight back against the trans agenda” by investigating medical providers; senior FTC staff publicly accusing medical associations of “malpractice” and disparaging journalists covering trans issues; and a 2025 FTC workshop that dismissed gender dysphoria as “science fiction” and framed the debate as a “battle of good versus evil.”

Notably, a workshop participant who advocated for investigating medical associations to cut their members and revenue was later hired by the FTC, underscoring the administration’s intent to weaponize government agencies against transgender health proponents.

Judge Boasberg emphasized that the subpoenas were not just empty threats but tools designed to chill speech and intimidate organizations regardless of any formal enforcement. He cited a recent D.C. Circuit ruling that blocked a similar retaliatory subpoena, underscoring that Congress never intended to allow agencies to trample First Amendment rights.

This ruling is a critical victory for transgender rights and medical freedom, pushing back against an authoritarian administration’s campaign of censorship and retaliation. It protects the privacy and advocacy work of organizations fighting to provide gender-affirming care amid relentless political attacks.

As WPATH stated, the court’s decision “rejects the government’s unlawful and retaliatory attempt to silence medical experts and advocates.” In a time when authoritarian overreach threatens democratic norms and civil rights, this ruling stands as a vital defense of free speech and the right to healthcare.